Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.25

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average rating of “Moderate Buy” from the eleven research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $32.2513.

Several equities analysts recently issued reports on BCAX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicara Therapeutics in a research report on Saturday, September 27th. Piper Sandler started coverage on Bicara Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price target on the stock. HC Wainwright cut their price target on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, August 12th.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in Bicara Therapeutics by 278.4% during the 4th quarter. Bank of America Corp DE now owns 33,677 shares of the company’s stock worth $587,000 after purchasing an additional 24,777 shares during the period. Nuveen LLC acquired a new stake in shares of Bicara Therapeutics during the 1st quarter valued at about $326,000. New York State Common Retirement Fund acquired a new stake in shares of Bicara Therapeutics during the 1st quarter valued at about $52,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $190,000. Finally, Nuveen Asset Management LLC acquired a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $436,000.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $17.04 on Friday. The stock’s fifty day moving average price is $11.83 and its 200 day moving average price is $11.70. Bicara Therapeutics has a 1 year low of $7.80 and a 1 year high of $28.09. The company has a market cap of $929.70 million and a price-to-earnings ratio of -5.38.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04. Research analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.